Immunotherapy-Chemo cocktail shows promise for Hard-to-Treat bile duct cancer
NCT ID NCT07668453
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (gemcitabine and nab-paclitaxel) as a first treatment for people with biliary tract cancer that cannot be removed by surgery. The goal is to see if this combo can shrink tumors and improve survival. Thirty participants will all receive the same treatment, and researchers will monitor side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adebrelimab (immunotherapy) combined with gemcitabine and albumin-bound paclitaxel (chemotherapy)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with biliary tract cancer that cannot be surgically removed, potentially shrinking tumors and extending survival.
What could go wrong
This is a small, early-phase (Phase 2) study with only 30 participants, so results may not apply to all patients. The combination may cause significant side effects, and there is no guarantee it will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••